AlphaCore Capital LLC Makes New $145,000 Investment in Inogen, Inc $INGN

AlphaCore Capital LLC bought a new stake in Inogen, Inc (NASDAQ:INGN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 20,614 shares of the medical technology company’s stock, valued at approximately $145,000. AlphaCore Capital LLC owned about 0.08% of Inogen at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Acadian Asset Management LLC lifted its holdings in Inogen by 35.7% during the 1st quarter. Acadian Asset Management LLC now owns 1,028,322 shares of the medical technology company’s stock worth $7,325,000 after purchasing an additional 270,453 shares during the last quarter. DAFNA Capital Management LLC increased its position in Inogen by 119.4% during the 1st quarter. DAFNA Capital Management LLC now owns 458,065 shares of the medical technology company’s stock worth $3,266,000 after buying an additional 249,275 shares during the period. Nuveen LLC acquired a new stake in shares of Inogen during the first quarter worth $1,097,000. AQR Capital Management LLC boosted its position in shares of Inogen by 30.1% in the first quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock valued at $4,022,000 after acquiring an additional 130,381 shares during the period. Finally, Monaco Asset Management SAM boosted its position in shares of Inogen by 119.1% in the first quarter. Monaco Asset Management SAM now owns 167,594 shares of the medical technology company’s stock valued at $1,195,000 after acquiring an additional 91,094 shares during the period. Institutional investors own 89.94% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inogen in a research report on Monday. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Inogen has an average rating of “Hold” and an average target price of $11.00.

Inogen Stock Up 0.1%

INGN stock opened at $7.09 on Wednesday. Inogen, Inc has a 52 week low of $5.70 and a 52 week high of $12.91. The business has a 50-day simple moving average of $8.00 and a 200 day simple moving average of $7.35. The company has a market cap of $192.49 million, a PE ratio of -7.02 and a beta of 1.83.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Inogen had a negative net margin of 7.31% and a negative return on equity of 13.21%. The firm had revenue of $92.39 million for the quarter, compared to the consensus estimate of $92.20 million. Inogen has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts anticipate that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.